Cell adhesion molecules in the development and progression of malignant melanoma

Cancer and Metastasis Reviews

Volumn 18, Issue 3, 1999, Pages 345-357

  Johnson, Judith P ^a,b  

^a UNIVERSITY OF MUNICH   (Germany)

^b Institute for Immunology   (Germany)

Author keywords

v 3; catenin; E cadherin; ICAM 1; MUC18 MCAM; VLA 4

Indexed keywords

ACTIVATED LEUKOCYTE CELL ADHESION MOLECULE; BETA CATENIN; CADHERIN; CELL ADHESION MOLECULE; IMMUNOGLOBULIN; INTEGRIN; INTERCELLULAR ADHESION MOLECULE 1; NERVE CELL ADHESION MOLECULE; UVOMORULIN; VASCULAR CELL ADHESION MOLECULE 1; VERY LATE ACTIVATION ANTIGEN;

CANCER GROWTH; CANCER INVASION; CARCINOGENICITY; CELL ADHESION; KERATINOCYTE; MELANOMA; METASTASIS; PRIORITY JOURNAL; PROGNOSIS; REVIEW; VASCULAR ENDOTHELIUM;

ANIMALS; ANTIGENS, CD; ANTIGENS, CD146; CADHERINS; CELL ADHESION MOLECULES; HUMANS; INTEGRIN ALPHA4BETA1; INTEGRINS; MELANOMA; MEMBRANE GLYCOPROTEINS; MICE; NEURAL CELL ADHESION MOLECULES; RECEPTORS, LYMPHOCYTE HOMING;

EID: 0033376770     PISSN: 01677659     EISSN: None     Source Type: Journal    
DOI: 10.1023/A:1006304806799     Document Type: Review

References (107)

1. 1. Fidler IJ: Biology of melanoma metastasis. In: Bach CM, Houghton AN, Sober AJ, Soong S (eds) Cutaneous Melanoma. Quality Medical Publishing, 1998, pp 493-516
2. 2. Huang Y-W, Vitetta ES: Adhesion molecules as targets for cancer therapy. Histo Histopathol 12: 467-477, 1997
3. 3. Nesbit M, Herlyn M: Adhesion receptors in human melanoma progression. Invasion Metastasis 14: 131-146, 1994
4. 4. Hart IR, Birch M, Marshall JF: Cell adhesion receptor expression during melanoma progression and metastasis. Cancer Metastasis Rev 10: 115-128, 1991
5. 5. Clark WH, Elder DE, Guerry D4, Epstein MN: A study of tumor progression. The precursor lesions of superficial spreading and nodular melanoma. Human Pathol 15: 1147-1165, 1984
6. 6. Clark WH, Elder DE, Guerry D, Braitman LE, Trock BJ, Schultz D, Synnestvedt M, Halpern AC: Model predicting survival in stage I melanoma based on tumor progression. J Natl Cancer Inst 81: 1893-1904, 1989
7. 7. Guerry D, Synnestvedt M, Elder DE, Schultz D: Lessons from tumor progression: the invasive radial growth phase of melanoma is common, incapable of metastasis, and indolent. J Invest Dermatol 100: 342-345, 1993
8. 8. Chothia C, Jones EY: The molecular structure of cell adhesion molecules. Ann Rev Biochem 66: 823-862, 1997
9. 9. Edelmann GM: Cell adhesion molecules in the regulation of animal form and tissue pattern. Ann Rev Cell Biol 2: 81-116, 1986
10. 10. Springer TA: Traffic signals on endothelium for lymphocyte recirculation. Ann Rev Physiol 57: 827-872, 1995
11. 11. Buck CA: Adhesion mechanisms controlling cell-cell and cell-matrix interactions during the metastatic process. In: Mendelsohn J, Howley PM, Israel MA, Liotta LA (eds) The Molecular Basis of Cancer. W.B. Saunders, 1995, pp 172-205
12. 12. Danen EH, Van Muijen GN, Ruiter DJ: Role of integrins as signal transducing cell adhesion molecules in human cutaneous melanoma. Cancer Surv 24: 43-65, 1995
13. 13. Mortarini R, Anchini A: From adhesion to signalling: roles of integrins in the biology of human melanoma. Melanoma Res 3: 87-97, 1993
14. 14. Hynes RO: Integrins: versatility, modulation and signalling in cell adhesion. Cell 69: 11-25, 1992
15. 15. Hughes PE, Pfaff M: Integrin affinity modulation. Trends Cell Biol 8: 359-364, 1998
16. 16. Sanchez-Amdrid P, Cabanas C, Sanchez-Madrid F: Regulation of integrin function. Sem Cancer Biol 7: 99-109, 1996
17. 17. Natali PG, Nicotra MR, Cavaliere R, Giannarelli D, Bigotti A: Tumor progression in human malignant melanoma is associated with changes in alpha 6/beta 1 laminin receptor. Int J Cancer 49: 168-172, 1991
18. 18. Moretti S, Martini L, Berti E, Pinzi C, Giannotti B: Adhesion molecule profile and malignancy of melanocytic lesions. Melanoma Res 3: 235-239, 1993
19. 19. Schadendrof D, Gawlik C, Haney U, Ostmeier H, Suter L, Czarnetzki BM: Tumour progression and metastatic behaviour in vivo correlates with integrin expression on melanocytic tumours. J Pathol 170: 429-434, 1993
20. 20. Schadendorf D, Heidel J, Gawlik C, Suter L, Czarnetzki BM: Association with clinical outcome of expression of VLA-4 in primary cutaneous malignant melanoma as well as P-selectin and E-selectin on intratumoral vessels. J Natl Cancer Inst 87: 366-371, 1995
21. 21. Albeda SM, Mette SA, Elder DE, Stewart R, Damajanovich L, Herlyn M, Buck CA: Integrin distribution in malignant melanoma: association of the β3 subunit with tumor progression. Cancer Res 50: 6757-6764, 1990
22. 22. Danen EH, Jansen KF, Van Kraats AA, Cornelissen IM, Ruiter DJ, Van Muijen GN: Alpha v-integrins in human melanoma: gain of alpha v beta 3 and loss of alpha v beta 5 are related to tumor progression in situ but not to metastatic capacity of cell lines in nude mice. Int J Cancer 61: 491-496, 1995
23. 23. Danen EH, Ten Berge PJ, Van Muijen GN, Van't Hof Grootenboer AE, Brocker EB, Ruiter DJ: Emergence of alpha 5 beta 1 fibronectin-and alpha v beta 3 vitronectinreceptor expression in melanocytic tumour progression. Histopathology 24: 249-256, 1994
24. 24. van Belle PA, Elenitsas R, Satyamoorthy K, Wolfe JT, Guerry D, Schuchter L, van Belle TJ, Albelda SM, Tahin P, Herlan M, Elder DE: Progression-related expression of beta3 integrin in melanomas and nevi. Hum Pathol 30: 562-567, 1999
25. 25. Lobb RR, Hemler ME: The pathophysiologic role of alpha4 integrins in vivo. J Clin Invest 94: 1722-1728, 1994
26. 26. Rice GE, Bevilacqua MO: An inducible endothelial cell surface glycoprotein mediates melanoma adhesion. Science 246: 1303-1306, 1989
27. 27. Okahara H, Yagita H, Miyake K, Okumura K: Involvement of very late activation antigen 4 (VLA-4) and vascular cell adhesion molecule 1 (VCAM-1) in tumor necrosis factor alpha enhancement of experimental metastasis. Cancer Res 54: 3233-3236, 1994
28. 28. Garofalo A, Chirivi RG, Foglieni C, Pigott R, Mortarini R, Martin Padura I, Anichini A, Gearing AJ, Sanchez Madrid F, Dejana E: Involvement of the very late antigen 4 integrin on melanoma in interleukin 1-augmented experimental metastases. Cancer Res 55: 414-419, 1995
29. 29. Danen EHJ, Marcinklewicz C, Cornelissen IMHA, Van Kraats AA, Pachter JA, Ruiter DJ, Niewiarowski S, Van Muijen GN: The disintegrin eristostatin interferes with integrin alpha 4 beta 1 function and with experimental metastasis of human melanoma cells. Exp Cell Res 238: 188-196, 1998
30. 30. Qian F, Vaux DL, Weissman IL: Expression of the integrin alpha 4 beta 1 on melanoma cells can inhibit the invasive stage of metastasis formation. Cell 77: 335-347, 1994
31. 31. Altevogt P, Hubbe M, Ruppert M, Lohr J, von Hoegen P, Sammar M, Andreq DP, McEvoy L, Humphries MJ, Butcher EC: The alpha 4 integrin chain is a ligand for alpha 4 beta 7 and alpha 4 beta 1. J Exp Med 182: 345-355, 1995
32. 32. Huhtala P, Humphries MJ, McCarthy JB, Tremble PM, Werb Z, Damsky CH: Cooperative signalling by alpha 5 beta 1 and alpha 4 beta 1 integrin regulates metalloproteinase gene expression in fibroblasts adhering to fibronectin. J Cell Biol 129: 867-879, 1995
33. 33. Marshall JF, Hart IR: The role of alpha v integrins in tumour progression and metastasis. Sem Cancer Biol 7: 129-138, 1996
34. 34. Nip J, Brodt P: The role of the integrin vitronectin receptor, alpha v beta 3 in melanoma metastasis. Cancer Metastasis Rev 14: 241-252, 1995
35. 35. Montgomery AM, Becker JC, Siu CH, Lemmon VP, Cheresh DA, Pancook JD, Zhao X, Reisfeld RA: Human neural cell adheison molecule L1 and rat homologue NILE are ligands for integrin alpha v beta 3. J Cell Biol 132: 475-485, 1996
36. 36. Brooks PC, Clark RA, Cheresh DA: Requirement of vascular integrin alpha v beta 3 for angiogenesis. Science 264: 569-571, 1994
37. 37. Rüegg C, Yilmaz A, Bieler G, Bamat J, Chaubert P, Lejeune FJ: Evidence for the involvement of endothelial cell integrin alphaV beta3 in the disruption of the tumor vasculature induced by TNF and IFN gamma. Nature Med 4: 408-414, 1998
38. 38. Natali PG, Nicotra MRDFF, Bigotti A: Expression of fibronectin, fibonectin isoforms and integrin receptors in melanocytic lesions. Brit J Cancer 71: 1243-1247, 1995
39. 39. Hieken TJ, Farolan M, Ronan SG, Shilkaitis A, Wild L, Das Gupta TK: β3 integrin expression in melanoma predicts subsequent metastasis. J Surg Res 63: 169-173, 1996
40. 40. Hieken TJ, Ronan SG, Farolan M, Shilkaitis AL, Das Gupta TK: Molecular prognostic markers in intermediate-thickness cutaneous malignant melanoma. Cancer 85: 375-382, 1999
41. 41. Natali PG, Hemby CV, Felding-Habermann B, Liang B, Nicotra MR, Di Filippo F, Giannarelli D, Temponi M, Ferrone S: Clinical significance of alpha(v)beta3 integrin and intercelluar adhesion molecule-1 expression in cutaneous malignant melanoma lesions. Cancer Res 57: 1554-1560, 1997
42. 42. Danen EHJ, Van Kraats AA, Cornelissen IMHA, Ruiter DJ, Van Muijen GN: Integrin β3 cDNA transfection into a highly metastatic alpha v β3 negative human melanoma cell line inhibits invasion and experimental metastasis. Biochem Biophys Res Commun 226: 75-81, 1996
43. 43. Boukerche H, Benchaibi M, Berthier Vergnes O, Lizard G, Bailly M, McGregor JL: Two human melanoma cell-line variants with enhanced in vivo tumor growth and metastatic capacity do not express the beta 3 integrin subunit. Eur J Biochem 220: 485-491, 1994
44. 44. Hsu MY, Shih D-T, Meier FE, Van Belle P, Hsu J-Y, Elder DE, Buck CA, Herlyn M: Adneoviral gene transfer of β3 integrin subunit induced conversion from radial to vertical growth phase in primary human melanoma. Am J Pathol 153: 1435-1442, 1998
45. 45. Satyamoorthy K, Dejesus E, Linnenbach A, Kraj B, Kornreich DL, Rendle S, Elder DE, Herlyn M: Melanoma cell lines from different stages of progression and their biological and molecular analyses. Melanoma Res 7: S35-S42, 1997
46. 46. Montgomery AM, Reisfeld RA, Cheresh DA: Integrin alpha v beta 3 rescues melanoma cells from apoptosis in three-dimensional dermal collagen. Proc Natl Acad Sci USA 91: 8856-8860, 1994
47. 47. Schneller M, Vuori K, Ruoslahti E: Alpha v β3 integrin associated with activated insulin and PDGFβ receptors and potentiates the biological activity of PDGF. EMBO J 16: 5600-5607, 1997
48. 48. Seftor REB, Seftor EA, Gehlsen KR, Stetler-Stevenson WG, Brown PD, Ruoslahti E, Hendrix MJC: Role of the alpha v beta 3 integrin in human melanoma cell invasion. Proc Natl Acad Sci USA 89: 1557-1561, 1992
49. 49. Nip J, Rabbani SA, Shibata HR, Brodt P: Coordinated expression of the vitronectin receptor and the urokinase-type plasminogen activator receptor in metastatic melanoma cells. J Clin Invest 95: 2096-2103, 1995
50. 50. Burns FR, von Kannen S, Guy L, Raper JA, Kamholz J, Chang S: DM-GRASP, a novel immunoglobulin superfamily axonal surface protein that supports neurite extension. Neuron 7: 209-220, 1991
51. 51. Pourquie O, Corbel C, La Caer JP, Rossier J, LeDouarin NM: BEN, a surface molecule of the immunoglobulin superfamily expressed in a variety of developing systems. Proc Natl Acad Sci USA 89: 5261-5265, 1992
52. 52. Bowen MA, Patel DD, Li X, Modrell B, Malacko AR, Wang WC, Marquardt H, Neubauer M, Pesando JM, Francke U, Haynes BF, Aruffo A: Cloning, mapping and characterization of activated leukocyte-cell adhesion molecule (ALCAM), a CD6 ligand. J Exp Med 181: 2213-2220, 1995
53. 53. Degen WGJ, van Kempen LCLT, Gijzen EGA, van Groningen JJM, van Kooyk Y, Bloemers HPJ, Swart GWM: MEMD, a new cell adhesion molecule in metastasizing human melanoma cell lines, is identical to ALCAM (activated leukocyte cell adhesion molecule). Am J Pathol 152: 805-813, 1998
54. 54. Johnson JP, Rummel MM, Rothbächer U, Sers C: MUC18: a cell adhesion molecule with a potential role in tumor growth and tumor cell dissemination. Cur Topics Micro Immunol 213(I): 95-105, 1996
55. 55. Johnson JP: The V-V-C2-C2-C2 cell adhesion molecule subfamily of the immunoglobulin superfamily. In: Kreis T, Vale R (ed) Guidebook to the Extracellular Matrix Anchor and Adhesion Proteins. Oxford University Press, 1999, pp 562-565
56. 56. Lehmann JM, Holzmann B, Breitbart EW, Schmiegelow P, Riethmüller G, Johnson JP: Discrimination between benign and malignant cells of melanocytic lineage by two novel antigens, a glycoprotein with a molecular weight of 113,000 and a protein with a molecular weight of 76,000. Cancer Res 47: 841-845, 1987
57. 57. Lehmann JM, Riethmüller G, Johnson JP: MUC18, a marker of tumor progression in human melanoma shows sequence similarity to the neural cell adhesion molecules of the immunoglobulin superfamily. Proc Natl Acad Sci USA 86: 9891-9895, 1989
58. 58. Holzmann B, Bröcker EB, Lehmann JM, Ruiter DJ, Sorg C, Riethmüller G, Johnson JP: Tumor progression in human melanoma: five stages defined by their antigenic phenotypes. Int J Cancer 39: 466-471, 1987
59. 59. Denton KJ, Streich J, Gatter KC, Harris AL: A study of adhesion molecules as markers of progression in malignant melanoma. J Pathol 167: 187-191, 1992
60. 60. Shih IM, Elder DE, Speicher D, Johnson JP, Herlyn M: Isolation and functional characterization of the A32 melanoma-associated antigen. Cancer Res 54: 2514-2520, 1994
61. 61. Kraus A, Masat L, Johnson JP: Analysis of the expression of intercellular adhesion molecule-1 and MUC18 on benign and malignant melanocytic lesions using monoclonal antibodies directed against distinct epitopes and recognizing denatured, non-glycosylated antigen. Melanoma Res 7s: 75-81, 1997
62. 62. Pickl WF, Majdic O, Fischer GF, Petzelbauer P, Fae I, Waclavicek M, Stöckl JSC, Vidicki T, Aschauer H, Johnson JP, Knapp W: MUC18/MCAM: an activation associated surface molecule of human T lymphocytes. J Immunol 158: 2107-2115, 1997
63. 63. Bardin N, Frances V, Lesaule G, Horschowski N, George F, Sampol J: Identification of the S-Endo 1 endothelial associated antigen. Biochem Biophys Res Commun 218: 210-216, 1996
64. 64. Bani MR, Rak J, Adachi D, Wiltshire R, Trent JM, Kerbel RS, Ben-David Y: Multiple features of advanced melanoma recapitulated in tumorigenic variants of early stage (radial growth phase) human melanoma cell lines: evidence for a dominant phenotype. Cancer Res 56: 3075-3086, 1996
65. 65. Luca M, Hunt B, Bucana CD, Johnson JP, Fidler IJ, Bar-Eli M: Direct correlation between MUC18 expression and metastatic potential of human melanoma cells. Melanoma Res 3: 35-41, 1993
66. 66. Xie S, Luca M, Huang S, Gutman M, Reich R, Johnson JP, Bar-Eli M: Expression of MCAM/MUC18 by human melanoma cells leads to increased tumor growth and metastasis. Cancer Res 57: 2295-2303, 1997
67. 67. Schlagbauer-Wadl H, Jansen B, Müller MPP, Wölf K, Eichler H-G, Perhamberger H, Konak E, Johnson JP: Influence of MUC18/MCAM/CD146 expression on human melanoma growth and metastasis in scid mice. Int J Cancer 81: 951-955, 1999
68. 68. Shih I-M, Speicher DW, Hus M-Y, Levine E, Herlyn M: Melanoma cell-cell interactions are mediated through heterophilic Mel-CAM/ligand adhesion. Cancer Res 57: 3835-3840, 1997
69. 69. Johnson JP, Bar-Eli M, Jansen B, Markhof E: Melanoma progression-associated glycoprotein MUC18/MCAM mediates homotypic cell adhesion through interaction with a heterophilic ligand. Int J Cancer 73: 769-774, 1997
70. 70. Walsh FS, Doherty P: Neural cell adhesion molecules of the immunoglobulin superfamily: role in axon growth and guidance. Ann Rev Cell Dev Biol 13: 425-456, 1999
71. 71. Anfosso F, Bardin N, Frances V, Vivier E, Camoin-Jau L, Sampol J, Dignat-George F: Activation of human endothelial cells via S-endo-1 antigen (CD146) stimulates the tyrosine phosphorylation of focal adhesion kinase p125-FAK. J Biol Chem 41: 26852-26856, 1998
72. 72. Schlaepfer DD, Hunter T: Integrin signalling and tyrosine phosphorylation: just the FAKs? Trends Cell Biol 8: 151-157, 1998
73. 73. Holzmann B, Johnson JP, Kaudewitz P, Riethmuller G: In situ analysis of antigens on malignant and benign cells of the melanocyte lineage. Differential expression of two surface molecules. gp75 and p89. J Exp Med 161: 366-377, 1985
74. 74. Johnson JP, Stade BG, Holzman B, Schwäble W, Riethmüller G: De novo expression of cell adhesion molecule ICAM-1 in melanoma and increased risk of metastasis. Proc Natl Acad Sci USA 86: 641-644, 1989
75. 75. Natali PG, Nicotra MR, Cavaliere R, Bigotti A, Romano G, Temponi M, Ferrone S: Differential expression of intercellular adhesion molecule 1 in primary and metastatic melanoma lesions. Cancer Res 50: 1271-1278, 1990
76. 76. Miele ME, Bennett CF, Miller BE, Welch DR: Enhanced metastatic ability of TNF-alpha-treated malignant melanoma cells is reduced by intercellular adhesion molecule-1 (ICAM-1, CD54) antisense oligonucleotides. Exp Cell Res 214: 231-241, 1994
77. 77. Van De Stolpe A, Van Der Saag PT: Intercellular adhesion molecule-1. J Mol Med 74: 13-33, 1996
78. 78. Mulder WM, Stern PL, Stukart MJ, de Windt E, Butzelaar RM, Meijer S, Ader HJ, Claessen AM, VermorkenJB, Meijer CJ, Wagstaff J, Scheper RJ, Bloemena E: Low intercellular adhesion moelcule 1 and high 5T4 expression on tumor cells correlate with reduced disease-free survival in colorectal carcinoma patients. Clin Cancer Res 3: 1923-1930, 1997
79. 79. Ogawa Y, Hirakawa K, Nakata B, Fujihara T, Sawada T, Kato Y, Yoshikawa K, Sowa M: Expression of intercellular adhesion molecule-1 in invasive cancer reflects low growth potential, negative lymph node involvement, and good prognosis. Clin Cancer Res 4: 31-36, 1998
80. 80. Aeed PA, Nakajima M, Welch DR: The role of polymorphonuclear leukocytes (PMN) on the growth and metastatic potential of 13762NF mammary adenocarcinoma cells. Int J Cancer 42: 748-759, 1988
81. 81. Giavazzi R, Chirivi RGS, Garofalo A, Rambaldi A, Hemingway I, Pigott R, Gearing AJH: Soluble intercellular adhesion molecule 1 is released by human melanoma cells and is associated with tumor growth in nude mice. Cancer Res 52: 2628-2630, 1992
82. 82. Becker JC, Termeer C, Schmidt RE, Brocker EB: Soluble intercellular adhesion molecule-1 inhibits MHC-restricted specific T cell/tumor interaction. J Immunol 151: 7224-7232, 1993
83. 83. Takeichi M: Cadherins: a molecular family important in selective cell-cell adhesion. Ann Rev Biochem 59: 237-252, 1990
84. 84. Yap AS, Brieher WM, Gumbiner BM: Molecular and functional analysis of cadherin-based adherens junctions. Ann Rev Cell Dev Biol 13: 119-146, 1997
85. 85. Matsuyoshi N, Tanaka T, Toda K, Imamura S: Identification of novel cadherins expressed in human melanoma cells. J Invest Dermatol 108: 908-913, 1997
86. 86. Hsu M-Y, Wheelock MJ, Johnson KR, Herlyn M: Shifts in cadherin profiles between human normal melanocytes and melanomas. J Invest Dermatol Symp Proc 1: 188-194, 1996
87. 87. Sanders DSA, Blessing K, Hassan GAR, Bruton R, Marsden JR, Jankowski J: Alterations in cadherin and catenin expression during the biological progression of melanocytic tumours. J Clin Pathol Mol Pathol 52: 151-157, 1999
88. 88. Birchmeier W, Behrens J. Cadherin expresion in carcinomas: role in the formation of cell junctions and the prevention of invasiveness. Biochem Biophys Acta 1198: 11-26, 1994
89. 89. Vleminckx K, Vakaet Jr L, Mareel M, Fiers W, Van Roy F: Genetic manipulation of E-cadherin expression by epithelial tumor cells reveals an invasion suppressor role. Cell 66: 107-119, 1991
90. 90. Perl A-K, Wilgenbus P, Dahl U, Semb H, Christofori G: A causal role for E-cadherin in the transition from adenoma to carcinoma. Nature 392: 190-193, 1998
91. 91. Tang A, Eller MS, Hara M, Yaar M, Hirohashi S, Gilchrest BA: E-cadherin is the major mediator of human melanocyte adhesion to keratinocytes in vitro. J Cell Sci 107: 983-992, 1994
92. 92. Valyi Nagy IT, Hirka G, Jensen PJ, Shih IM, Juhasz I, Herlyn M: Undifferentiated keratinocytes control growth, morphology, and antigen expression of normal melanocytes through cell-cell contact [see comments]. Lab Invest 69: 152-159, 1993
93. 93. Shih IM, Elder DE, Hsu MY, Herlyn M: Regulation of Mel-CAM/MUC18 expression on melanocytes of different stages of tumor progression by normal keratinocytes. Am J Pathol 145: 837-845, 1994
94. 94. Cowley GP, Smith ME: Cadherin expression in melanocytic nevi and malignant melanoma. J Pathol 179: 183-187, 1996
95. 95. Silye R, Karayiannakis AJ, Syrigos KN, Poole S, van Noorden S, Batchelor W, Regele H, Sega W, Boesmueller H, Krausz T, Pignatelli M: E-cadherin/catenin complex in benign and malignant melanocytic lesions. J Pathol 186: 350-355, 1998
96. 96. Danen EHJ, de Vries TJ, Morandini R, Ghanem GG, Ruiter DJ, van Muijen GNP: E-cadherin expression in human melanoma. Melanoma Res 6: 127-131, 1996
97. 97. Ozawa M, Engel J, Kemler R: Single amino acid substitutions in one calcium binding site of uvomorulin abolish the adhesive function. Cell 63: 1033-1038, 1990
98. 98. Robbins PF, El-Gamil M, Yong FL, Kawakami Y, Loftus D, Appella E, Rosenberg SA: A mutated β-catenin gene encodes a melanoma-specific antigen recognized by tumor infiltrating lymphocytes. J Exp Med 183: 1185-1192, 1996
99. 99. Rubinfield B, Robbins P, El-Gamil M, Albert I, Porfiri E, Polakis P: Stabilization of β-catenin by genetic defects in melanoma cell lines. Science 275: 1790-1793, 1997
100. 100. Rimm DL, Caca K, Hu G, Harrison FB, Fearon ER: Frequent nuclear/cytoplasmic localization of β-catenin without exon 3 mutations in malignant melanoma. Am J Path 154: 325-329, 1999
101. 101. Willert K, Nusse R: β-catenin: a key mediator of wnt signaling. Curr Opin Genet Dev 8: 95-102, 1988
102. 102. Klymkowsky MW, Parr B: The body language of cells: the intimate connection between cell adhesion and behavior. Cell 83: 5-8, 1995
103. 103. Jankowski JA, Bruton R, Shepherd N, Sanders DSA: Cadherin and catenin biology represent a global mechanism for epithelial cancer progression. J Clin Pathol Mol Pathol 50: 289-290, 1997
104. 104. Grimm T, Johnson JP: Ectopic expression of carcinoembryonic antigen by a melanoma cell leads to changes in the transcription of two additional cell adhesion molecules. Cancer Res 55: 3254-3257, 1995
105. 105. Wodarz A, Nusse R: Mechanisms of wnt signaling in development. Ann Rev Cell Dev Biol 14: 59-88, 1998
106. 106. Novak A, Hsu S-C, Leung-Hagesteijn C, Radeva G, Papkoff J, Montesano R, Roskelley C, Grosschedl R, Dedhar S: Cell adhesion and the integrin-linked kinase regulate the LRF-I and β-catenin signaling pathways. Proc Natl Acad Sci USA 95: 4374-4379, 1998
107. 107. Erickson CA: From the crest to the periphery: control of pigment cell migration and lineage segregation. Pigment Cell Res 6: 336-347, 1993